Literature DB >> 1521818

Toxicity of 1-(beta-D-arabinofuranosyl)cytosine after intravitreal injection in the rabbit eye.

J J Diets-Ouwehand1, R J de Keizer, G F Vrensen, S Groen-Jansen, J A van Best.   

Abstract

The retinal toxicity of intravitreally injected 1-(beta-D-arabinofuranosyl)cytosine (cytarabine) was examined in 7 chinchilla rabbits to determine if cytarabine can be used as local therapy for vitreoretinal non-Hodgkin's lymphoma. Fractionated dose of 600 micrograms, 1500 micrograms, and 2700 micrograms cytarabine in stabilized saline were given intravitreally in one eye (2 x 300 micrograms, 5 x 300 micrograms, and 3 x 900 micrograms, respectively, with an interval time of 24 h) and stabilized saline in the other eye as control. Toxic effects were evaluated with biomicroscopy, direct ophthalmoscopy, fluorophotometry, electroretinography, light, and electron microscopy. Toxic effects were found with the 1500 micrograms and 2700 micrograms doses only. They consisted of a temporary impairment of the blood retina barrier function for fluorescein as measured by fluorophotometry and an irreversible change of the b-wave in the electroretinograms. No histopathologic changes were seen under the light microscope. Electron microscopic examination showed aberrations in the synaptic pedicles of the photoreceptor cells at a dose of 1500 micrograms cytarabine. The results suggest that the cytarabine dose that is expected to be therapeutic for vitreoretinal non-Hodgkin's lymphoma (about 90 micrograms given in three doses of 30 micrograms) is non-toxic for ocular structures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1521818     DOI: 10.1007/bf00175939

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  33 in total

Review 1.  Ocular and orbital tumors.

Authors:  M C Kincaid
Journal:  Ophthalmology       Date:  1988-11       Impact factor: 12.079

2.  Non-Hodgkin's lymphoma of the corpus vitreum.

Authors:  W Sizoo; J G van Andel; G S Baarsma; J J Wielenga
Journal:  Neth J Med       Date:  1988-08       Impact factor: 1.422

Review 3.  The eclectroretinogram: its components and their origins.

Authors:  K T Brown
Journal:  Vision Res       Date:  1968-06       Impact factor: 1.886

4.  The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.

Authors:  A L Harris; D G Grahame-Smith
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Effects of high-dose cytarabine.

Authors:  K R Hande; R S Stein; D A McDonough; F A Greco; S N Wolff
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

6.  Update of ocular reticulum cell sarcoma.

Authors:  H A Sloas; J Starling; D G Harper; H P Cupples
Journal:  Arch Ophthalmol       Date:  1981-06

7.  Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management.

Authors:  D H Char; B M Ljung; T Miller; T Phillips
Journal:  Ophthalmology       Date:  1988-05       Impact factor: 12.079

8.  Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes.

Authors:  A Barrada; G A Peyman; J Case; G Fishman; A Thomas; R Fiscella
Journal:  Ophthalmic Surg       Date:  1984-09

9.  Ocular reticulum cell sarcoma.

Authors:  D H Char; L Margolis; A B Newman
Journal:  Am J Ophthalmol       Date:  1981-04       Impact factor: 5.258

10.  Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma).

Authors:  M J Siegel; J Dalton; A H Friedman; J Strauchen; C Watson
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.